Bristol Myers Squibb reports 2-year Psoriatic Arthritis data for Sotyktu

Bristol Myers Squibb said its Sotyktu (POETYK PsA-2 OLE) psoriatic arthritis results showed maintained efficacy and consistent safety through Week 104, with observed ACR20/50/70 responses of 76.9%/54.6%/37.7% and no new safety signals.